FDA Approves This Company For Breakthrough Liver Disease Treatment

Altimmune's Pemvidutide Gets Fast Track Designation by FDA: A Major Step Forward in the Treatment of Non-Alcoholic Steatohepatitis (NASH).

Altimmune Inc., a clinical-stage biopharmaceutical company, has been granted Fast Track designation by the U.S. Food and Drug Administration (FDA) for Pemvidutide, its investigational drug for the treatment of non-alcoholic steatohepatitis (NASH). This is a significant breakthrough that could potentially change the lives of millions of people worldwide …